Evidence-Based Neonatal Pharmacotherapy: Postnatal Corticosteroids

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 47-59

  Watterberg, Kristi ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchopulmonary dysplasia; Cardiovascular insufficiency; Dexamethasone; Hydrocortisone; Hypotension; Newborn infant; Preterm infant

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE FACTOR; INDOMETACIN; OXYGEN; PLACEBO; PREDNISONE;

ADRENAL INSUFFICIENCY; AREA UNDER THE CURVE; BRAIN HEMORRHAGE; COHORT ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; ENCEPHALOMALACIA; EVIDENCE BASED MEDICINE; HEAD CIRCUMFERENCE; HEART HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; LUNG DYSPLASIA; NEWBORN; NEWBORN CARE; NONHUMAN; OPEN STUDY; OXYGEN CONSUMPTION; OXYGEN THERAPY; PERINATAL PERIOD; POSTNATAL CARE; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; PROTEIN METABOLISM; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SHOCK; SIDE EFFECT; TREATMENT RESPONSE; VERY LOW BIRTH WEIGHT; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; DEXAMETHASONE; EVIDENCE-BASED MEDICINE; HUMANS; HYDROCORTISONE; HYPOTENSION; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK; VASOCONSTRICTOR AGENTS;

EID: 84857071158     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.017     Document Type: Review

References (87)

1. Williams H.W., Dluhy R.G. Diseases of the adrenal cortex. Harrison's principles of internal medicine 1998, 2035-2057. McGraw-Hill Companies, New York. 14th edition. A.S. Fauci, E. Braunwald, K.J. Isselbacher (Eds.).
2. De Kloet R.E., Vreugdenhil E., Oitzl M.S., et al. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998, 19:269-301.
3. McEwen B.S. The brain is an important target of adrenal steroid actions: a comparison of synthetic and natural steroids. Ann N Y Acad Sci 1997, 823:201-213.
4. Schimmer B.P., Parker K.L. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Goodman & Gilman's the pharmacologic basis of therapeutics 2001, 1649-1677. McGraw-Hill, New York. 10th edition. J.G. Hardman, L.E. Limbird (Eds.).
5. Meikle A.W., Tyler F.H. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977, 63:200-207.
6. Crochemore C., Lu J., Wu Y., et al. Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 2005, 10:790-798.
7. Hassan A.H., von Rosenstiel P., Patchev V.K., et al. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol 1996, 140:43-52.
8. Isaacs E.B., Lucas A., Chong W.K., et al. Hippocampal volume and everyday memory in children of very low birth weight. Pediatr Res 2000, 47:713-720.
9. Giménez M., Junqué C., Narberhaus A., et al. Hippocampal gray matter reduction associates with memory deficits in adolescents with history of prematurity. Neuroimage 2004, 23:869-877.
10. Nosarti C., Al-Asady M.H., Frangou S., et al. Adolescents who were born very preterm have decreased brain volumes. Brain 2002, 125:1616-1623.
11. Murphy B.P., Inder T.E., Huppi P.S., et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001, 107:217-221.
12. Parikh N.A., Lasky R.E., Kennedy K.A., et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 2007, 119:265-272.
13. Thompson D.K., Wood S.J., Doyle L.W., et al. Neonate hippocampal volumes: prematurity, perinatal predictors, and 2-year outcome. Ann Neurol 2008, 63:642-651.
14. Rademaker K.J., Uiterwaal C.S., Groenendaal F., et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007, 150:351-357.
15. Rademaker K.J., Rijpert M., Uiterwaal C.S., et al. Neonatal hydrocortisone treatment related to 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res 2006, 59:309-313.
16. Parikh N.A., Lasky R., Tyson J., et al. Does low dose hydrocortisone improve volumetric MRI measures of cerebral growth in extremely low birth weight infants at high risk for bronchopulmonary dysplasia?: a randomized trial [abstract]. Presented at the annual meeting of Pediatric Academic Societies. E-PAS 2009, 3212.2.
17. Tam E.W., Chau V., Ferriero D.M., et al. Preterm cerebellar growth impairment after postnatal exposure to glucocorticoids. Sci Transl Med 2011, 3:105ra105.
18. Buttgereit F., Brand M.D., Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999, 58:363-368.
19. Noori S., Friedlich P., Wong P., et al. Hemodynamic changes after low-dosage hydrocortisone administration in vasopressor-treated preterm and term neonates. Pediatrics 2006, 118:1456-1466.
20. Howard E. Reductions in size and total DNA of cerebrum and cerebellum in adult mice after corticosterone treatment in infancy. Exp Neurol 1968, 22:191-208.
21. Howard E., Benjamin J.A. DNA, ganglioside and sulfatide in brains of rats given corticosterone in infancy, with an estimate of cell loss during development. Brain Res 1975, 92:73-87.
22. De Souza S.W., Adlard B.P. Growth of suckling rats after treatment with dexamethasone or cortisol. Implications for steroid therapy in human infants. Arch Dis Child 1973, 48:519-522.
23. Mammel M.C., Green T.P., Johnson D.E., et al. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983, 1(8338):1356-1358.
24. Avery G.B., Fletcher A.B., Kaplan M., et al. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985, 75:106-111.
25. Cummings J.J., D'Eugenio D.B., Gross S.J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989, 320:1505-1510.
26. Metzger D.L., Wright N.M., Veldhuis J.D., et al. Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysis. J Clin Endocrinol Metab 1993, 77:458-463.
27. Yeh T.F., Torre J.A., Rastogi A., et al. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr 1990, 117:273-282.
28. Kothadia J.M., O'Shea T.M., Roberts D., et al. Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999, 104:22-27. [erratum appears in Pediatrics 2004;114:1746].
29. Yeh T.F., Lin Y.J., Huang C.C., et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998, 101:E7.
30. O'Shea T.M., Kothadia J.M., Klinepeter K.L., et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999, 104:15-21.
31. Barrington K.J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001, 1:1.
32. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004, 350:1304-1313.
33. Papile L.A., Tyson J.E., Stoll B.J., et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med 1998, 338:1112-1118.
34. Tsai F.J., Tsai C.H., Wu S.F., et al. Catabolic effect in premature infants with early dexamethasone treatment. Acta Paediatr 1996, 85:1487-1490.
35. Zecca E., Papacci P., Maggio L., et al. Cardiac adverse effects of early dexamethasone treatment in preterm infants: a randomized clinical trial. J Clin Pharmacol 2001, 41:1075-1081.
36. Garland J.S., Alex C.P., Pauly T.H., et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics 1999, 104:91-99.
37. Stark A.R., Carlo W.A., Tyson J.E., National Institute of Child Health and Human Development Neonatal Research Network, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001, 344:95-101.
38. Walsh M.C., Yao Q., Horbar J.D., et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006, 118:e1328-e1335.
39. Committee on Fetus and Newborn Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002, 109:330-338.
40. Doyle L.W., Davis P.G., Morley C.J., DART Study Investigators, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006, 117:75-83.
41. Doyle L.W., Davis P.G., Morley C.J., DART Study Investigators, et al. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 2007, 119:716-721.
42. Durand M., Mendoza M.E., Tantivit P., et al. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002, 109:262-268.
43. McEvoy C., Bowling S., Williamson K., et al. Randomized, double-blinded trial of low-dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 2004, 38:55-63.
44. Yates H.L., Newell S.J. Minidex: very low dose dexamethasone (0.05 mg/kg/day) in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2011, 96:F190-F194.
45. Tanney K., Davis J., Halliday H.L., et al. Extremely low-dose dexamethasone to facilitate extubation in mechanically ventilated preterm babies. Neonatology 2011, 100:285-289.
46. Watterberg K.L., American Academy of Pediatrics. Committee on Fetus and Newborn Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010, 126:800-808.
47. Onland W., Offringa M., De Jaegere A.P., et al. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 2009, 123:367-377.
48. Onland W., van Kaam A.H., De Jaegere A.P., et al. Open-label glucocorticoids modulate dexamethasone trial results in preterm infants. Pediatrics 2010, 126:e954-e964.
49. Doyle L.W., Halliday H.L., Ehrenkranz R.A., et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005, 115:655-661.
50. Ehrenkranz R.A., Walsh M.C., Vohr B.R., National Institutes of Child Health and Human Development Neonatal Research Network, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005, 116:1353-1360.
51. Gargus R.A., Vohr B.R., Tyson J.E., et al. Unimpaired outcomes for extremely low birth weight infants at 18 to 22 months. Pediatrics 2009, 124:112-121.
52. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Early (<8 days) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, 1. CD001146.
53. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, 1. CD001145.
54. Watterberg K.L., Gerdes J.S., Gifford K.L., et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999, 104:1258-1263.
55. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004, 114:1649-1657.
56. Peltoniemi O., Kari M.A., Heinonen K., et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005, 146:632-637.
57. Bonsante F., Latorre G., Iacobelli S., et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007, 91:217-221.
58. Watterberg K.L., Scott S.M. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995, 85:120-125.
59. Huysman M.W., Hokken-Koelega A.C., De Ridder M.A., et al. Adrenal function in sick very preterm infants. Pediatr Res 2000, 48:629-633.
60. Watterberg K.L., Scott S.M., Backstrom C., et al. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 2000, 105:320-324.
61. Watterberg K.L., Gerdes J.S., Cook K.L. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res 2001, 50:190-195.
62. Nykänen P., Anttila E., Heinonen K., et al. Early hypoadrenalism in premature infants at risk for bronchopulmonary dysplasia or death. Acta Paediatr 2007, 96:1600-1605.
63. Doyle L.W., Ehrenkranz R.A., Halliday H.L. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010, 98:111-117.
64. Watterberg K.L., Shaffer M.L., Mishefske M.J., et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007, 120:40-48.
65. Peltoniemi O.M., Lano A., Puosi R., et al. Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology 2009, 95:240-247.
66. Mazela J., Polin R.A. Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur J Pediatr 2011, 170:433-444.
67. Watterberg K.L., Clark A.R., Kelly H.W., et al. Delivery of aerosolized medication to intubated babies. Pediatr Pulmonol 1991, 10:136-141.
68. Köhler E., Jilg G., Avenarius S., et al. Lung deposition after inhalation with various nebulisers in preterm infants. Arch Dis Child Fetal Neonatal Ed 2008, 93:F275-F279.
69. Shah S.S., Ohlsson A., Halliday H., et al. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2007, 4. CD002057.
70. Shah V., Ohlsson A., Halliday H.L., et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2007, 4. CD001969.
71. Laughon M., Bose C., Allred E., et al. Factors associated with treatment for hypotension in extremely low gestational age newborns during the first postnatal week. Pediatrics 2007, 119:273-280.
72. Fernandez E.F., Watterberg K.L., Kendrick D., et al. Incidence, management and short term outcomes of hypotension in the critically ill term and late preterm newborn [abstract]. Presented at the annual meeting of Pediatric Academic Societies. E-PAS 2011, 3832.305.
73. Logan J.W., O'Shea T.M., Allred E.N., et al. Early postnatal hypotension and developmental delay at 24 months of age among extremely low gestational age newborns. Arch Dis Child Fetal Neonatal Ed 2011, 96:F321-F328.
74. Dempsey E.M., Al Hazzani F., Barrington K.J. Permissive hypotension in the extremely low birthweight infant with signs of good perfusion. Arch Dis Child Fetal Neonatal Ed 2009, 94:F241-F244.
75. Soleymani S., Borzage M., Seri I. Hemodynamic monitoring in neonates: advances and challenges. J Perinatol 2010, 30(Suppl):S38-S45.
76. Helbock H.J., Insoft R.M., Conte F.A. Glucocorticoid-responsive hypotension in extremely low birth weight newborns. Pediatrics 1993, 92:715-717.
77. Scott S.M., Watterberg K.L. Effect of gestational age, postnatal age, and illness on plasma cortisol concentrations in premature infants. Pediatr Res 1995, 37:112-116.
78. Ng P.C., Lee C.H., Lam C.W., et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2004, 89:F119-F126.
79. Cooper M.S., Stewart P.M. Adrenal insufficiency in critical illness. J Intensive Care Med 2007, 22:348-362.
80. Ng P.C., Lee C.H., Bnur F.L., et al. A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 2006, 117:367-375.
81. Higgins S., Friedlich P., Seri I. Hydrocortisone for hypotension and vasopressor dependence in preterm neonates: a meta-analysis. J Perinatol 2010, 30:373-378.
82. Yoder B., Martin H., McCurnin D.C., et al. Impaired urinary cortisol excretion and early cardiopulmonary dysfunction in immature baboons. Pediatr Res 2002, 51:426-432.
83. Bourchier D., Weston P.J. Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1997, 76:F174-F178.
84. Finer N.N., Powers R.J., Ou C.H., California Perinatal Quality Care Collaborative Executive Committee, et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics 2006, 117:704-713.
85. Reynolds J.W., Colle E., Ulstrom R.A. Adrenocortical steroid metabolism in newborn infants. V. Physiologic disposition of exogenous cortisol loads in the early neonatal period. J Clin Endocrinol Metab 1962, 22:245-254.
86. Watterberg K.L., Cook K., Gifford K.L. Pharmacokinetics of hydrocortisone in extremely low birth weight infants in the first week of life. Pediatr Res 1996, 39:251A.
87. Watterberg KL, Shaffer ML, for the PROPHET study group. Cortisol concentrations and apparent serum half-life during hydrocortisone therapy in extremely low birth weight infants. PAS 2005;57:1501.